The Department of Defense’s (DoD) Peer-Reviewed Medical Research Program (PRMRP) has determined the grant applications that it wishes to award in fiscal year 2021 (FY21). In this first year that applications were accepted for research in peripheral neuropathy, 41 applications out of over 1000 applications received focused on peripheral neuropathy. DoD is recommending awarding a grant […]
Last week, the Chairman of the Senate Committee on Appropriations released the Majority’s draft of the fiscal year 2022 (FY22) Defense Appropriations Act. The Foundation for Peripheral Neuropathy is pleased to see that this draft legislation once again includes “peripheral neuropathy” among the eligible conditions for grants in FY22 from the Department of Defense’s Peer […]
Read More… from Peripheral Neuropathy is Again an Eligible Condition for DOD Grants
Mark Vieth, Senior Vice President at Cavarocchi Ruscio Dennis Associates and the Foundation for Peripheral Neuropathy’s advocacy consultant in Washington, D.C., confirmed that the president and Congressional leaders recently reached an important two-year budget deal, paving the way for the Senate to complete its spending bills in September. As a result, in early September, the […]
Read More… from Call to Action! Help Us Get Your Voice Heard for More Research Funding!
On July 9, 2018, the Federal Drug Administration (FDA) held a public forum focusing on the patient’s perspective on drug development for chronic pain. The FDA invited members of the public, including the Foundation for Peripheral Neuropathy’s (FPN) President, Lou Mazawey, to attend to give their perspectives on living with chronic pain and treatment approaches […]
Read More… from FDA and FPN survey patients on chronic pain and treatments
On December 3, 2015, Astellas Pharma US, Inc. (the U.S. affiliate of Astellas Pharma Inc.), a R&D-driven global pharmaceutical company, invited the Foundation for Peripheral Neuropathy to present to a global team working on development of ASP3662 for patients with neuropathic pain (NP). This was an internal meeting, which included Ulf Tollemar, Executive Director, Development […]